gest significant variability in ICU utilization. Some hospitals routinely admit patients with NSTEMI to the ICU, whereas others may attempt to select patients at risk of clinical deterioration for ICU admission.
Location of care may have important implications. A previous study 6 of Medicare beneficiaries diagnosed with pneumonia found that ICU care was associated with lower adjusted mortality. Although ICU care has not been associated with reduced mortality in all patients with myocardial infarction (MI), 4 whether hemodynamically stable but higher-risk patients specifically derive benefit has not been tested. It is also uncertain whether hospitals effectively triage patients with NSTEMI at higher mortality risk to the ICU. The National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines (ACTION Registry-GWTG) collects data for consecutive patients with MI treated in routine practice in the United States and is unique in capturing sufficient clinical information to calculate predicted mortality risk on admission. Using this registry, which has been linked to Centers for Medicare & Medicaid Services claims records to provide information on ICU utilization, we aimed to (1) describe current practice patterns and interhospital variability in ICU utilization for older patients with NSTEMI, (2) determine whether hospitals selectively treated older patients at higher mortality risk in the ICU, and (3) examine the association of hospital ICU utilization rates with 30-day mortality based on patients' mortality risk on admission.
Methods

Patient Population
The ACTION Registry-GWTG is a quality improvement registry that captures consecutive patients admitted to participating hospitals with STEMI and NSTEMI. 7, 8 Trained data abstractors at each hospital collect detailed information on medical history, clinical presentation, and in-hospital treatment via retrospective medical record review. Real-time data quality feedback and annual audits ensure data accuracy. Patients 65 years or older in the ACTION Registry-GWTG have previously been linked to their Centers for Medicare & Medicaid Services claims data using 5 indirect identifiers (date of birth, sex, hospital identifier, date of admission, and date of discharge). [9] [10] [11] We used this linked data source to determine ICU utilization and postdischarge outcomes. The Duke University Medical Center institutional review board granted a waiver of informed consent and authorization for this study.
Of 44 915 patients with NSTEMI in the linked database from April 1, 2011, through December 31, 2012, we excluded 12 433 patients who initially presented to hospitals that do not participate in the ACTION Registry-GWTG and were transferred from those hospitals into ACTION Registry-GWTG hospitals because the triaging decision for these patients depends on hospital policies, physician preference, variations in the amount of information conveyed before transfer, and patient characteristics at the time of transfer that introduce substantial risk of unmeasured confounding. We excluded patients with cardiac arrest (n = 688) or cardiogenic shock (n = 473) on admission because these patients had a compelling reason for ICU admission. For patients with multiple MI admissions during the study period (n = 1348), follow-up began at the start of the first admission. Finally, to ensure reasonable precision of hospitalspecific ICU utilization rates, 153 hospitals admitting fewer than 25 patients with MI during the study period were excluded (n = 1955). To ensure that hospitals reporting 0% ICU utilization for patients with NSTEMI had ICU capability, we cross-referenced the ACTION Registry-GWTG database with data from the American Hospital Association survey; all hospitals reporting 0% ICU utilization had ICU beds. Data analysis was performed from May 7 through October 8, 2015.
Statistical Analysis
Patients with revenue center codes for ICU or coronary care unit utilization (eAppendix 1 in the Supplement) during the index MI hospitalization were classified as having been treated in an ICU. After examination of the distribution curve, we divided hospitals into 3 groups: high ICU utilization (>70% of all patients with NSTEMI treated in the ICU), intermediate ICU utilization (30%-70%), and low ICU utilization (<30%). We compared hospital features, patient characteristics, and treatment patterns during the index hospitalization of patients with NSTEMI treated at high, intermediate, and low ICU utilization hospitals. Categorical variables were reported as frequencies with percentages and compared using χ 2 tests, and continuous variables were reported as medians with interquartile ranges (IQRs) and compared using Kruskal-Wallis tests. Relevance Utilization of the ICU by older patients with NSTEMI is common and varies substantially among hospitals.
Key Points
risk score was derived and validated in a population of patients with MI and predicts in-hospital mortality (C statistic = 0.84) based on variables present on presentation: age, baseline serum creatinine, systolic blood pressure, baseline troponin level (times the upper limit of normal [ULN]), heart rate, presence of heart failure or shock, electrocardiographic changes, and prior peripheral arterial disease. On the basis of cut points defined in the initial derivation of the ACTION risk score, we divided patients into groups with ACTION risk scores of greater than 40, 30 to 40, and less than 30, corresponding to high, moderate, and low predicted in-hospital mortality risk, respectively. Box plots of ACTION risk score, as a continuous variable, were displayed for patients with and without an ICU stay across hospital ICU utilization categories. We then compared the proportion of patients with ACTION risk scores greater than 40, 30 to 40, and less than 30 treated in an ICU among high, intermediate, and low ICU utilization hospitals using a χ 2 test.
We repeated this analysis, dividing patients into different risk categories based on their initial troponin levels: less than 1 × ULN, 1 to 10 × ULN, and greater than 10 × ULN. We compared unadjusted 30-day mortality from the time of index admission among high, intermediate, or low ICU utilization hospitals. Unadjusted 30-day mortality was first reported among all patients with NSTEMI and then stratified by ACTION risk score. We used logistic generalized estimating equations regression with an exchangeable working correlation matrix to account for within-hospital clustering and to adjust for patient and hospital characteristics. 13 Odds ratios (ORs) and 95% CIs were reported, with low ICU utilization hospitals as the reference group. To account for our inability to determine whether patients were directly admitted to the ICU or transferred to the ICU after sustaining an in-hospital complication and to minimize the influence of unmeasured illness severity that biases toward ICU utilization, we performed a sensitivity analysis excluding patients with any documented complication mandating ICU admission during the index hospitalization. Documented complications mandating ICU care included in-hospital development of cardiogenic shock, cardiac arrest, or stroke as captured by the ACTION Registry-GWTG data collection form and patients with diagnosis or procedure codes that mandate ICU-level care: those indicating hemodynamic compromise requiring inotrope, vasopressor, or mechanical support; need for cardiopulmonary resuscitation; arrhythmia requiring pacing; mechanical complication after MI; respiratory failure; stroke; or intracranial hemorrhage (eAppendix 3 in the Supplement). We repeated the above analyses, examining hospital rate of ICU utilization and association with 30-day mortality after excluding these patients.
We observed low rates of missing data: less than 1% for all variables except body mass index (1.1%) Missing values in continuous covariates were imputed to the sex-specific median of the nonmissing values. For categorical variables, missing values were imputed by the most frequent group. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute Inc). The Duke Clinical Research Institute conducted all analyses. (Table) .
Results
Rates of ICU Utilization
Predicted Risk and ICU Utilization
Characteristics of patients admitted to high, intermediate, and low ICU utilization hospitals are presented in the Table. Differences in clinical characteristics, including comorbid illnesses, severity of illness on presentation, and other markers of MI severity (such as peak troponin level and ejection fraction) of patients with NSTEMI treated at high, intermediate, and low ICU utilization hospitals were statistically significant, although differences may be too small to be clinically meaningful. The median ACTION risk score was 33 (IQR, 27-40); 33.5% of patients had an ACTION risk score less than 30, 43.5% had an ACTION risk score of 30 to 40, and 23.0% had an ACTION risk score greater than 40. The distribution of ACTION risk scores was similar among patients with NSTEMI treated at high, intermediate, and low ICU utilization hospitals. Observed in-hospital mortality was 1% for patients with ACTION risk scores less than 30, 3% for those with ACTION risk scores of 30 to 40, and 11% for those with ACTION risk scores greater than 40. We observed statistically significant but very small differences in median ACTION risk score between patients with and without an ICU stay, regardless of hospital-level ICU utilization (Figure 2) . At low and intermediate ICU utilization hospitals, the median ACTION risk score for a patient not treated in an ICU was 33 compared with 34 for patients treated in the ICU.
In low and intermediate ICU utilization hospitals, patients with ACTION risk scores greater than 40 were more likely than those with lower ACTION risk scores to receive ICU care; this pattern was not evident at high ICU utilization hospitals (Figure 3) . Patients with an admission troponin level greater than 10 × ULN were significantly more likely to receive care in an ICU than those with lower admission troponin levels at all hospitals, but the difference was larger at low and intermediate ICU utilization hospitals (Figure 3) . Only 2236 patients (53.3%) and 629 patients (25.8%) with an admission troponin level greater than 10 × ULN received care in the ICU at intermediate and low ICU utilization hospitals, respectively. In high ICU utilization hospitals, greater than 85% of patients received care in the ICU regardless of initial troponin level.
ICU Utilization, In-Hospital Treatment, and 30-Day Mortality
Statistically significant differences in treatment were found with certain guideline-recommended medications and use of revascularization procedures at low ICU utilization hospitals compared with intermediate and high ICU utilization hospitals; however, the absolute differences among groups in the proportion of patients treated with any medication or procedure were small (<3%) ( Table) . Median length of hospital stay was slightly shorter at low ICU utilization hospitals compared with intermediate and high ICU utilization hospitals (3 vs 4 and 4 days). Median ICU length of stay was longer at high ICU utilization hospitals compared with low and intermediate ICU utilization hospitals (3 vs 2 and 2 days).
Within 30 days of the index admission, 2460 of 26 820 patients (9.2%) died. Unadjusted 30-day mortality was 8.7% at low ICU utilization hospitals, 9.6% at intermediate ICU utilization hospitals, and 8.7% at high ICU utilization hospitals; these rates were significantly different (P = .04). After adjusting for hospital characteristics and differences in patient case mix, hospitalization at high or intermediate ICU utilization hospitals vs low ICU utilization hospitals was not associated with significant differences in 30-day mortality (high vs low: OR, 0.91; 95% CI, 0.76-1.08; intermediate vs low: OR, 1.06; 95% CI, 0.94-1.20). The association between hospital ICU utilization and mortality did not change when considered among patients with ACTION risk scores greater than 40, 30 to 40, and less than 30 (adjusted interaction P = .86). When the effect of ICU utilization on mortality was evaluated as a continuous variable, increasing ICU utilization was not significantly associated with unadjusted (OR, 1.01; 95% CI, 0.99-1.04) or riskadjusted mortality (OR, 1.00; 95% CI, 0.97-1.02) per 10% increase in ICU utilization.
Sensitivity Analysis
Overall, 4396 patients (15.7%) had at least 1 documented complication that required ICU-level care: 1183 (13.3%) at low ICU utilization hospitals, 2621 (16.8%) at intermediate ICU utilization hospitals, and 592 (16.7%) at high ICU utilization hospitals (eTable in the Supplement). After exclusion of these patients, 8529 patients with NSTEMI (36.1%) were treated in an ICU. Interhospital variability remained in the proportion of patients treated in an ICU (eFigure in the Supplement); hospitals treated a median 
Discussion
In this nationwide study, we found that 42.6% of older patients hospitalized with NSTEMI received care in the ICU in the absence of cardiogenic shock or cardiac arrest on admission, with considerable interhospital variability in ICU utilization. The proportion of patients with NSTEMI treated in the ICU did not appear to be explained by differences in patient case mix or hospital type. The difference in ACTION risk score between patients treated with and without ICU care was small regardless of whether a hospital routinely or selectively uses ICUs for patients with MI. No difference was found in adjusted 30-day mortality between patients with NSTEMI treated at high or intermediate vs low ICU utilization hospitals, even among patients with higher in-hospital mortality risk. Prior studies, 3-5 conducted using administrative data sources, also revealed variability in ICU utilization for patients with MI and found no association between hospital-level ICU utilization and mortality. The NCDR collected data on each patient's MI type, hemodynamic status, troponin level, and other covariates, allowing for the calculation of mortality risk on admission; thus, it extends these prior findings by offering a unique perspective on how illness severity may factor into ICU utilization. Although most patients with STEMI (80%) are treated in an ICU, 4 hospitals varied substantially in the location of care for older patients with NSTEMI. No significant differences were found in hospital characteristics (including size, teaching status, and revascularization capability) across high, intermediate, and low ICU utilization hospitals. Differences in ICU utilization between hospitals also did not appear to be explained by patient case mix. Importantly, the wide interhospital variation in ICU utilization rates persisted after excluding patients with a documented indication for ICU care. High ICU utilization hospitals are likely to routinely triage older patients with NSTEMI to the ICU, resulting in more than 70% of these patients having at least a 1-day ICU stay. As expected, the predicted mortality of ICU-treated patients was similar to that of patients not treated in the ICU at these hospitals. In intermediate and low ICU utilization hospitals, practitioners selectively triaged patients to the ICU, resulting in 30% to 70% and less than 30% of these patients receiving care in the ICU, respectively. However, at these hospitals, higher-risk patients were only slightly more likely to receive care in the ICU; the difference in median ACTION risk scores between patients treated in and outside an ICU was small. Practitioners may not routinely calculate a mortality risk score to guide ICU triaging. However, the ACTION risk score, like other mortality risk scores (eg, Global Registry of Acute Coronary Events or Thrombolysis in Myocardial Infarction), 14, 15 is essentially a synthesis of clinical variables that practitioners might use to determine illness severity or project patient risk. 12 Alternatively, practitioners might stratify risk simply based on initial degree of troponin level elevation. When patients were stratified by troponin levels, low and intermediate ICU utilization hospitals still did not appear to be triaging patients with higher troponin levels to the ICU. The results of our analysis suggest that ICU triage is largely driven by local practices and practitioner preference. In that light, it is unsurprising to observe no difference in 30-day mortality between patients with NSTEMI treated at high or intermediate vs low ICU utilization hospitals. The lack of mortality benefit from treatment at a high ICU utilization hospital may stem from the low likelihood of developing a life-threatening, post-MI complication mandating ICU care in the modern era. [16] [17] [18] These findings have important implications for decision making with regard to location of care for initially stable patients with NSTEMI. Although our data did not allow for the examination of hospital charges related to ICU care vs care in a non-ICU ward, a previous study 19 found a difference of more than $3500 per day. With almost half of the 450 000 patients with NSTEMI treated each year in the United States being admitted to the ICU for a median stay of 2 days, expenditures on ICU care alone for NSTEMI may exceed $1.2 billion annually. Although an association between volume and outcome has been demonstrated in many conditions, a previous study 20 failed to identify an association between ICU MI volume and outcomes. A more selective ICU utilization strategy may be preferable for cost reasons; however, some initially stable patients will ultimately require ICU care, and no risk model has been developed to identify these patients before clinical deterioration. Several study limitations need to be acknowledged. Our study could not determine whether patients were triaged electively to the ICU or transferred after clinical deterioration; therefore, we performed a sensitivity analysis to exclude all patients who developed a clear indication for ICU care with results similar to our primary analysis. Second, in an observational setting, we cannot infer a causal relationship between ICU utilization and mortality, and we cannot exclude the possibility of unmeasured confounding. Third, our study grouped hospitals by observed ICU utilization rates but did not capture protocols that hospitals use in making ICU triage decisions; the ACTION Registry-GWTG also did not capture variables, such as persistent chest pain or dynamic electrocardiographic changes, which may be used in triage decisions. Finally, this analysis is limited to older patients who receive Medicare benefits, and the results may not be generalizable to younger patients.
Conclusions
In this study of older patients hospitalized with NSTEMI, we found that ICU utilization was common even in patients with uncomplicated NSTEMI, that there was considerable variability in hospital patterns of ICU utilization that did not appear to be explained by hospital characteristics or patient mortality risk, and that hospitals did not appear to triage patients at the highest predicted risk to the ICU. We observed no difference in 30-day mortality among patients with NSTEMI treated at high or intermediate vs low ICU utilization hospitals. Additional research is needed to identify the optimal strategy of ICU admission in patients with NSTEMI, but more judicious use of ICU admission, with a focus on identifying patients most likely to require ICU-level care, could result in similar outcomes but significant cost savings. 
